Idiopathic pulmonary fibrosis (IPF) is characterized by a disturbed pulmonary redox balance associated with inflammation. To restore this balance, antioxidants are often suggested as therapy for IPF but previous clinical trials with these compounds and their precursors have not been successful in the clinic. The exogenous antioxidant quercetin, which has a versatile antioxidant profile and is effective in restoring a disturbed redox balance, might be a better candidate. The aim of this study was to evaluate the protective effect of quercetin on oxidative and inflammatory markers in IPF. Here, we demonstrate that IPF patients have a significantly reduced endogenous antioxidant defense, shown by a reduced total antioxidant capacity and lowered glutathione and uric acid levels compared to healthy controls. This confirms that the redox balance is disturbed in IPF. Ex vivo incubation with quercetin in blood of both IPF patients and healthy controls reduces LPS-induced production of the pro-inflammatory cytokines IL-8 and TNFα. This anti-inflammatory effect was more pronounced in the blood of the patients. Our pro-fibrotic in vitro model, consisting of bleomycin-triggered BEAS-2B cells, shows that quercetin boosts the antioxidant response, by increasing Nrf2 activity, and decreases pro-inflammatory cytokine production in a concentration-dependent manner. Collectively, our findings implicate that IPF patients may benefit from the use of quercetin to restore the disturbed redox balance and reduce inflammation.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and lethal disease of unknown cause with a median survival of only 3-5 years which is worse than that of several types of cancer (e.g., breast, bladder, and colorectal) (Woodcock and Maher, 2014; Raghu et al., 2011a; Vancheri et al., 2010) . It is the most common and severe form of idiopathic interstitial lung diseases that affects mainly 60-to 70-year old ever smokers (Raghu et al., 2011a) . This disease is characterized by an excessive and uncontrolled reparative process following chronic alveolar epithelial microinjuries, leading to excessive scarring of the lungs which impairs the ability of the lungs to transport oxygen (Zoz et al., 2011; King et al., 2011) . While IPF is by definition "idiopathic" (i.e., of unknown cause), the list of potential fibrogenic triggers that have been associated with IPF includes, among others, cigarette smoking, exposure to man-made fibers and chronic infection (King et al., 2011) . Key clinical feature is a cruelly impaired lung function, ultimately leading to death from respiratory failure (King et al., 2011) . In the US only, IPF affects between 150,000-200,000 people, and as many as 40,000 people die from this disease each year (Raghu et al., 2014) . Similar incidence, prevalence and mortality rates have been reported in Europe with for example a yearly incidence of approximately 1000-1500 new cases in the Netherlands (Meltzer and Noble, 2008; Navaratnam et al., 2011) .
IPF is characterized by a disturbed pulmonary redox-balance due to a chronic overload of ROS in comparison to protective antioxidants (Kuwano et al., 2003; Rahman et al., 2012) . The increased ROS production is suggested to play a critical role in epithelial activation and injury of the alveolar cells including damage to DNA, lipids and proteins which ultimately causes severe tissue damage thereby contributing to the progression of the disease (Lenz et al., 1996; Hecker et al., 2012; Ushio-Fukai and Nakamura, 2008) .
Moreover, increased ROS levels are critical in driving the progression of IPF mainly via triggering the activation and release of active TGF-β1, that augments the existing inflammation and lung scarring (Arts et al., 2004) . Furthermore, ROS mediate TGF-β1-induced fibrogenesis including activation and proliferation of fibroblasts, differentiation into myofibroblasts causing secretion of ECM molecules and excessive collagen deposition, activation of pro-inflammatory cells and induction of EMT (Cheresh et al., 2013) .
Under normal circumstances, the endogenous antioxidant defense system provides sufficient protection against ROS (Bast et al., 1991) but in patients burdened with IPF this system may be overloaded. Part of the pulmonary antioxidant defense system is regulated by the redox sensitive transcription factor nuclear factor eryrhroid 2-related factor 2 (Nrf2) (Cheresh et al., 2013) . In the presence of oxidative stress, Nrf2 translocates into the nucleus where it will bind to the antioxidant response elements (ARE) that will induce the transcription of antioxidant genes (Cho et al., 2006) . Nrf2 is upregulated in IPF to restore the pulmonary redox status but not to a sufficient enough level, leaving IPF patients exposed to elevated ROS levels (Singh et al., 2010a) . Consequently, antioxidant therapy to strengthen such a reduced antioxidant defense might be efficacious in IPF treatment. Since ROS are capable of initiating and mediating inflammation, antioxidant therapy might also mitigate the elevated pro-inflammatory response.
Despite the fact that numerous large clinical trials have been conducted over the last few years since Raghu et al. published the IPF guidelines for diagnosis and management, there is still no effective cure for IPF that increases survival (Raghu et al., 2011b) . Consequently, current standard treatment still consists of anti-inflammatory and immunosuppressive agents, aiming at reducing symptoms and the underlying inflammation (Raghu et al., 2011a) . Moreover, current IPF treatments such as pirfenidone and N-acetyl-L-cysteine (NAC) aiming at decreasing oxidative stress in the lungs do show a clinical benefit but fail to be completely successful. The latest update of these guidelines therefore acknowledges the need for further research regarding the pathology of the disease as well as the efficacy and long-term safety of IPF medications to improve the outcome of the disease and the patient's quality of life (Raghu et al., 2015) .
Alternatively, other strong antioxidants with a more versatile character, including those present in our daily diet, have already been suggested as good candidates for antioxidant therapy in interstitial lung diseases (ILD) including IPF (Bast et al., 2010) . The dietary antioxidant quercetin (3,3′,4′,5,7-pentahydroxyflavone) for instance is a prototypical polyphenolic plant flavonoid which is mainly present in vegetables and fruit as well as in tea and red wine (D'Andrea, 2015) . It is suggested that quercetin is the most potent scavenger of ROS, including superoxide, within the flavanoid family (D'Andrea, 2015) . By activating the Nrf2 pathway, it also indirectly exerts its function through induction of Nrf2-regulated genes to further increase specific protection against oxidants (Numazawa and Yoshida, 2004; Surh et al., 2008) . However, quercetin is not only known for its strong anti-oxidative but also for its anti-inflammatory capacities both in vitro (Boots et al., 2008; Gauliard et al., 2008) and in various pulmonary models (Impellizzeri et al., 2015; Wang et al., 2014; Takashima et al., 2014) . Additionally, studies indicate that it is also effective in restoring a disturbed redox balance and reducing inflammation in vivo in other interstitial lung diseases (ILD) such as sarcoidosis (Boots et al., 2009; Boots et al., 2011) .
The aim of the present study is to evaluate the antioxidant and inflammatory status in IPF as well as the possible beneficial effects of the dietary antioxidant quercetin hereon. To this end, the protective effects of quercetin on the antioxidant defense and inflammatory markers have been determined both in vitro in pulmonary epithelial cells and ex vivo in LPS-stimulated blood of IPF patients. We hypothesize that the antioxidant and inflammatory status in IPF are compromised and that quercetin can offer protection against oxidant-induced lung damage by restoring the disturbed redox balance and decreasing levels of inflammatory markers.
Materials & methods

Clinical study
11 non-smoking patients with IPF, diagnosed according to the guidelines (Raghu et al., 2011a) , were enrolled in this study via recruitment in our outpatient clinic (Table 1) . The control group, matched on age and gender, consisted of 9 non-smoking healthy controls. Based on food questionnaires, all patients and controls had comparable dietary habits with an average daily quercetin intake of 15 mg. The Medical Ethical Committee of the Maastricht University Medical Center had approved the protocol and the study was registered at http://www.clinicaltrials.gov (NCT-00512967). All participants have given their written informed consent.
Lung function measurement
Forced vital capacity (FVC) and forced expiratory volume in one second (FEV 1 ) were measured with a pneumotachograph (Masterlab, Jaeger, Würzburg, Germany). The diffusing capacity of the lung for carbon monoxide (DLCO) was measured using the single-breath method (Masterlab) (Quanjer et al., 1993) .
Cell culture and treatments
The human bronchial epithelial cell line BEAS-2B was obtained from the American Type Culture Collection (ATCC, Rockville, MD) and maintained in DMEM/F12 supplemented with cholera toxin (10 ng/ mL), epidermal growth factor (10 ng/mL), insulin (5 μg/mL), transferin (5 μg/mL), dexamethasone (0.1 μM), bovine pituitary extract (15 μg/ mL) and bovine serum albumin (0.5 mg/mL). Cells were pretreated for 30 min with 10, 25 or 50 μM quercetin (Sigma, St. Lois, MO) or 0.1% ethanol (vehicle control) and subsequently exposed to different concentrations (0.1, 0.3, 1, 3, 10, 30 μg/mL) bleomycin for various time periods (2 h, 4 h, 24 h or 48 h).
Preparation of blood samples
Blood was collected in EDTA-containing vacutainer tubes (BectonDickinson, Franklin Lakes, NJ) and kept on ice prior to processing.
Trolox antioxidant capacity
The trolox equivalent antioxidant capacity (TEAC value) is a measurement for the total antioxidant status, assessing the capacity of a compound to scavenge ABTS radicals. This assay has been performed as described earlier (Fischer et al., 2005) with some minor modifications. In short, blood was centrifuged (3000 rpm, 5′ at 4°C) and plasma was afterwards deproteinized, using 10% TCA (1:1) followed by Toxicology and Applied Pharmacology 336 (2017) 40-48 centrifugation (13.000 rpm, 5′ at 4°C). A solution of 0.23 mM ABTS (2,2′-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid)) and 2.3 mM ABAP (2,2′-Azobis-(2-amidinopropane)HCl) was incubated at 70°C to generate ABTS radicals (ABTS •) until the absorbance at 734 nm reached 0.70 ± 0.02. To measure the antioxidant capacity of the samples, 50 μl of the plasma sample was mixed with 950 μl ABTS • solution and incubated for 5 min at 37°C. The decrease in absorbance was measured at 734 nm and related to the absorbance of trolox standards to calculate the trolox equivalent of the samples.
2.6. Measurement of endogenous antioxidants 2.6.1. Vitamin C To asses vitamin C in the blood, 10% TCA was added and blood samples were centrifuged (5000 rpm, 10′ at 4°C). Ascorbate oxidase (Roche Diagnostics, Basel, Switzerland) was added to the plasma samples, leading to the oxidation of vitamin C to dehydro-ascorbic acid. 0.1% (w:v) O-phenyleendiamin (OPDA) (Sigma) was added and incubated for 30 min at 37°C. HPLC analysis was performed using a Hypersil BDS column (125 mm × 2 mm, particle size 5 μm from Agilent, Palo Alto, CA) with excitation at 355 nm and emission at 425 nm and vitamin C content was quantified using calibrators.
Uric acid measurement
Shortly, deproteinated plasma samples was injected in the HPLC system with fluorescent detection. HPLC analysis was performed using a Hypersil BDS column (125 mm × 4 mm, particle size 5 μm from Agilent) with UV detection at 292 nm. Uric acid content of each sample was quantified using calibrators with known levels of uric acid.
GSH and GSSG
Prior to storage, 1.3% SSA in 10 mM HCl was added to the blood samples used for the determination of reduced glutathione (GSH) and oxidized glutathione (GSSG). All samples were centrifuged (5000 rpm, 10′ at 4°C) and supernatant was collected. For the GSH measurement, supernatant was added (1:1) to 0.6 mM 5-5′-dithiobis (2-nitrobenzoic acid) (DTNB) (Sigma) (37°C) and incubated for 15 s (37°C), and absorbance was measured at 412 nm. For the GSSG measurement, supernatant was added to 2-vinyl-pyridine (Sigma) (10:1) and incubated for 1 h at room temperature. Subsequently, a mixture of 0.6 mM DTNB and 0.8 mM NADPH (37°C) was added (1:9) and the reaction was started by adding the enzyme glutathione reductase (1:20). The absorbance was measured for 3 min at 412 nm. Both the GSH and GSSG content of each sample were quantified using calibrators and related to the haemoglobin content.
Blood-based cytokine production assay
Within 1 h after blood collection, the blood-based cytokine production assay was performed as described previously with minor modifications (Swennen et al., 2005) . Shortly, blood was diluted in RPMI 1640 (1:4, Gibco) and incubated with 1, 3 or 30 μM quercetin for 30 min. To induce cytokine production, lipopolysaccharide (LPS, E. coli 0.26:B6) (Sigma) was added and samples were incubated for 24 h at 37°C. Cell-free supernatant fluids were collected by centrifugation (6000 rpm, 10′ at 4°C) and stored at 20°C prior to cytokine analysis.
ELISA measurement
Plasma and supernatant TNFα and IL-8 levels were quantified using a human ELISA kit according to the manufacturer's instructions (Sanquin, Amsterdam, the Netherlands).
RNA isolation
RNA was isolated and purified using the RNeasy mini kit (Qiagen, Venlo, the Netherlands) according to the manufacturer's instructions. The RNA concentration was determined using a Nanodrop spectrophotometer (Thermo Scientific, Waltham, MA).
RT-PCR
cDNA was synthesized from 500 ng isolated RNA using IScript (Biorad, Hercules, CA) according to the manufacturer's instructions. RT-PCR was performed using SYBR Green PCR Supermix (BioRad) and PCR amplifications were carried out for 40 cycles of denaturation (95°C, 15 s), annealing (57°C, 15 s) and extension (60°C, 45 s) for selected genes ( Table 2 ). The gene expression was normalized to GAPDH using the ΔC T method.
Nrf2 activation
Nrf2 activation was measured in 10 μg nuclear extracts using the TransAM Nrf2 activation kit (Active Motif, Carlsbad, CA) according to manufacturer's instructions. The extracts were prepared using a nuclear extraction kit (Active Motif).
ROS production
For the 2,7-dichlorofluorescein diacetate (DCF-DA) assay, cells were incubated with 10 μM DCF-DA (Sigma) for 20 min at 37°C, stimulated with bleomycin and fluorescence was measured with excitation at 485 nm and emission at 525 nm.
Statistical analysis
Quantitative data are presented as mean ± SEMs. Two-sided differences between two groups were analyzed by unpaired t-tests. Differences among > 2 groups were determined by 1-way ANOVA. Differences were considered significant if P < 0.05.
Results
IPF patients have a decreased antioxidant capacity
IPF is characterized by the presence of oxidative stress, which is defined as an imbalance between the production of ROS and protection against ROS by antioxidants, driving the pro-fibrotic response (Arts et al., 2004; Kliment and Oury, 2010) . Although Nrf2 is upregulated in IPF to restore the pulmonary redox status, this protective response is not sufficient to protect against the elevated ROS level (Singh et al., 2010a) . Moreover, it is assumed that IPF patients have a dysregulated antioxidant response which is no longer able to counteract the increased ROS production. To evaluate the exact antioxidant status in our IPF patient group compared to healthy controls, the individual endogenous antioxidants GSH, vitamin C and uric acid are determined as well as the total plasma antioxidant capacity (Fig. 1) . Nrf2  ACACGGTCCACAGCTCATC  TCTTGCCTCCAAAGTATGTCAA  HO-1  CTTCTTCACCTTCCCCAACA  GCTCTGGTCCTTGGTGTC  y-GCS  GCACATCTACCACGCCGTC  CCACCTCATCGCCCCAC  Catalase  GACTGACCAGGGCATCAAAAA  CGGATGCCATAGTCAGGATCTT  IL-8  GGACAAGAGCCAGGAAGAAA  AAATTTGGGGTGGAAAGGTT  TNFα  TCAATCGGCCCGACTATCTC  CAGGGCAATGATCCCAAAGT  TGF-β1  CCCTGGACACCAACTATTGC  CTTCCAGCCGAGGTCCTT  Col1A1  AAGAGGAAGGCCAAGTCGAG  CACACGTCTCGGTCATGGTA  GAPDH  GAA GGC TGG GGC TCA TTT G  AGG CTG TTG TCA TAC TTC TCA  TGG C. Veith et al. Toxicology and Applied Pharmacology 336 (2017) 40-48 The concentration of GSH is 50% decreased in the blood of IPF patients compared to the age-, gender-and dietary behavior matched controls (6.6 ± 0.6 vs 12.9 ± 1.9 μM/mg Hb). GSSG levels do not significantly differ between the two groups (0.8752 ± 0.0926 vs 0.6874 ± 0.0996 μM/mg Hb) (Fig. 1A) .
The trolox equivalent antioxidant capacity (TEAC value) is a measurement for the total antioxidant status, relating the free radical scavenging properties of a solution or a compound to that of the synthetic antioxidant trolox. The total plasma antioxidant capacity in the blood of IPF patients is significantly declined compared to that of matched controls (483.1 ± 29.5 vs 619.7 ± 16.6 μM Trolox equivalent). The levels of the two endogenous antioxidants known to contribute substantially to the total plasma antioxidant status, i.e. uric acid (123.5 ± 17.9 vs 183.4 ± 14.4 μM) and vitamin C (54.3 ± 2.8 vs 63.1 ± 2.3 μM), are slightly decreased but vitamin C is not significantly changed in the plasma of IPF patients compared to controls (Fig. 1B) .
When the concentrations of uric acid and vitamin C are known, the relative contribution of these antioxidants to the total plasma antioxidant capacity can be calculated. This calculation shows that the major part of the total plasma antioxidant capacity is due to plasma antioxidants other than uric acid and vitamin C, including low molecular protein thiols. This residual plasma antioxidant capacity (also referred to as corrected TEAC) is slightly but not significant lower in the fibrosis group compared to the matched controls (Fig. 1C) , indicating that IPF patients have a lower overall antioxidant capacity that is not solely due to decreased levels of its major players vitamin C and uric acid.
Bleomycin increases ROS production which can be counteracted by quercetin
We showed that IPF patients have a decreased antioxidant capacity and it is therefore expected that oxidative stress and a reduced antioxidant defense contribute to the development of the disease.
The effects of the pro-fibrotic trigger bleomycin on intracellular ROS production, as well as the possible protective effects of the strong antioxidant quercetin hereon, are evaluated in BEAS-2B cells. Cytotoxicity is not influenced by the different treatments as cell viability after stimulation with bleomycin and quercetin is > 80% (data not shown).
Intracellular ROS production dose-dependently increases in response to bleomycin compared to the control ( Fig. 2A) with a 100% increase upon stimulation with 30 μg/mL bleomycin. Interestingly, pretreatment with various concentrations of the antioxidant quercetin leads to a concentration-dependent reduction of this bleomycin-induced ROS production with the strongest effect (50% reduction) occurring Fig. 1 . Idiopathic pulmonary fibrosis (IPF) patients have a decreased antioxidant capacity. Antioxidant status in IPF patients (n = 11) compared to their matched controls (n = 9). (A) GSH (μM/mg Hb) and GSSG (μM/mg Hb) measured in blood plasma. (B) Total antioxidant status (TEAC) (μM), vitamin C (μM) and uric acid (μM) in blood plasma. (C) Relative plasma antioxidant capacity as well as contribution of uric acid (μM) and vitamin C (μM) to the total antioxidant status. Data are expressed as mean ± SEM, *P < 0.05, **P < 0.01. Fig. 2 . Bleomycin dose-dependently induces ROS production and pretreatment with quercetin can reduce this induced oxidant burden. ROS production by BEAS-2B cells after stimulation with different bleomycin concentrations for 2 h using 10 μM DCF-DA (A) without or (B) with quercetin pretreatment. Values are presented as mean percentage of fluorescence in the absence of bleomycin ± SEM (n = 6), *P < 0.05, **P < 0.01.
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after pretreatment with 50 μM quercetin (Fig. 2B) . However, for further experiments 25 μM quercetin is chosen as a higher dose (50 μM) also induces a pro-inflammatory response in the cells (data not shown).
Quercetin boosts antioxidant response by increasing Nrf2 activity and induction of Nrf2-regulated genes
An increased ROS accumulation is known to induce the translocation of the redox-sensitive transcription factor Nrf2 to the nucleus, where it binds to the ARE causing gene transcription of antioxidant genes to compensate for oxidative stress in the cells (Cho et al., 2006) . The effect of both the ROS-inducing bleomycin and the protective antioxidant quercetin on Nrf2 activity was analyzed. To this end, the gene expression of Nrf2 and Nrf2-regulated genes as well as the Nrf2 binding capacity are studied.
Bleomycin induces a slight, yet not significant increase in the expression of Nrf2, a significant 50% decrease in the expression of the Nrf2-regulated gene heme-oxygenase (HO-) 1, a not significant reduction in Nrf2-regulated γ-glutamyl cysteine (γ-GCS) expression and no change in the expression of Nrf2-regulated catalase (Fig. 3A) . Interestingly, pretreatment with quercetin strongly enhances BLM-induced expression of Nrf2 as well as of the Nrf2-regulated genes HO-1 and gamma-GCS, but not catalase, compared to treatment with bleomycin alone (Fig. 3A) . Next, the Nrf2 binding capacity to the ARE was evaluated. Bleomycin has no effect on Nrf2 activity whereas quercetin pretreatment causes a 30% significant increase in Nrf2 ARE binding compared to both the control and bleomycin-treated cells (Fig. 3B) .
Bleomycin dose-dependently induces IL-8 expression and production which can be reduced by quercetin pretreatment
As previously described, inflammation plays an important role in the pathogenesis of IPF as the disease is characterized by the infiltration of inflammatory cells in the lungs (Bringardner et al., 2008) . Additionally, it is known that ROS production and inflammation are closely intertwined. The next step was to investigate the effects of bleomycin and quercetin on both the gene expression and protein levels of the pro-inflammatory cytokines tumor necrosis factor-α (TNFα) and interleukin-8 (IL-8) in vitro.
Bleomycin induces a 40-fold increase in IL-8 gene expression, whereas it does not affect TNFα gene expression (Fig. 4A) . Pretreatment with quercetin has no significant effect on this bleomycin-induced change in IL-8 gene expression.
Next, the effect of various bleomycin concentrations for 4 h and 24 h on the IL-8 and TNFα production was investigated to see whether bleomycin has a short or long term effect on these cytokines. Bleomycin concentration-dependently increases IL-8 production after 4 h as well as after 24 h (Fig. 4B and C) . Pretreatment with 10 μM quercetin has no effect on IL-8 production after 4 h whereas pretreatment with 25 μM quercetin can significantly reduce IL-8 production induced by 10 μg/mL bleomycin (Fig. 4D) . After 24 h incubation with bleomycin, 25 μM quercetin reduces this inflammatory response by 50% (Fig. 4E) . No increase in TNFα production can be measured upon bleomycin stimulation for either 4 or 24 h (data not shown).
IPF patients have a higher systemic inflammation which is reduced by quercetin ex vivo after LPS stimulation
Our in vitro data suggest that the pro-inflammatory response after bleomycin challenge is mainly mediated by oxidative stress as the antioxidant quercetin is capable of protecting against this induced damage. To evaluate pro-inflammatory cytokines and the inhibiting effect of quercetin hereon in IPF patients, the inflammatory status and response are assessed in the plasma of IPF patients and matched controls.
Basal plasma levels of both IL-8 and TNFα (Fig. 5A) show a significant increase in patients suffering from IPF compared to their controls (13.1 ± 2.1 pg/mL vs 7.8 ± 0.4 pg/mL for IL-8 and 20.2 ± 4.2 pg/mL vs 4.3 ± 0.3 pg/mL for TNFα).
To evaluate the anti-inflammatory effects of quercetin, inflammation is further evoked by ex vivo LPS-stimulation of the blood of both patients and controls. Ex vivo LPS-induced IL-8 and TNFα production are significantly decreased by quercetin in both the patient and the control group (Fig. 5B and C) . Moreover, the extent of this reduction depends on the quercetin concentration. TNFα responds more sensitive to quercetin in the fibrosis group, resulting in a significant larger decrease in both TNFα production compared to the matched controls. The same trend, although only significant for 30 μM quercetin, is visible for LPS-induced IL-8 production.
Discussion
The pathogenesis of IPF, which is clinically characterized by excessive tissue scarring and an impaired wound healing response due to continuous insults of the alveolar epithelium, has been associated with an increased accumulation of ROS, resulting in a disturbed redox balance (Arts et al., 2004; Kliment and Oury, 2010) . Recently, there has been a growing interest in the therapeutic use of strong natural antioxidants to prevent tissue damage induced by oxidative stress (Bast et al., 2010) . Although some recent studies have explored the importance of oxidative stress in the development of IPF, the overall benefits of antioxidants to prevent and protect against IPF are largely unknown. The antioxidant quercetin, mainly present in fruit and vegetables, is not only known for its strong anti-oxidative but also for its anti-inflammatory capacities both in vitro and in various pulmonary models (Boots et al., 2008; Gauliard et al., 2008) . Additionally, studies indicate that it is also effective in restoring a disturbed redox balance and reducing inflammation in vivo in other interstitial lung diseases (ILD) such as sarcoidosis (Impellizzeri et al., 2015; Wang et al., 2014) . Moreover, quercetin also showed beneficial effects in cell or mouse models of a variety of lung diseases including lung cancer 3 . Quercetin increases Nrf2 activation. (A) Gene expression of Nrf2 and Nrf2-regulated genes after stimulation with 10 μg/mL bleomycin for 4 h with or without pretreatment with 25 μM quercetin for 30 min. Values are presented as mean relative to GAPDH gene expression ± SEM (n=6), (B) Nrf2 DNA binding after stimulation with 10 μg/mL bleomycin for 4 h with or without pretreatment with 25 μM quercetin. Values are presented as mean percentage in the absence of bleomycin and quercetin ± SEM (n = 4), *P < 0.05, **P < 0.01.
C. Veith et al. Toxicology and Applied Pharmacology 336 (2017) 40-48 Based on these observations, we examined the potentially protective effects of the antioxidant quercetin, mainly present in fruit and vegetables, on markers of oxidative stress and inflammation in vitro and ex vivo in blood of IPF patients.
In summary, we show that IPF patients have a decreased antioxidant defense, indicated by a significantly reduced total antioxidant capacity, glutathione and uric acid concentrations in plasma compared to the controls. Our in vitro model displayed a dose-dependent increase in ROS production and reduced expression of Nrf2-driven genes after challenge with the pro-fibrotic trigger bleomycin, indicating that the cells are not capable of dealing with the increased amount of oxidative stress. Moreover, basal TNFα and IL-8 levels are significantly increased in the plasma of IPF patients concurrent with our pro-fibrotic in vitro model, in which IL-8 is dose-dependently increasing after bleomycin exposure. The dietary antioxidant quercetin boosts the antioxidant response in vitro, indicated by an increased expression of Nrf2 as well as Nrf2-regulated genes, including HO-1 and γ-GCS, and enhanced Nrf2 activity. The gene expression of catalase did not change after stimulation with bleomycin alone or in combination with quercetin. This can be explained by the facts that 1) catalase is not solely regulated by Nrf2, but also by other transcription factors including FoXO3a and PPARγ (Glorieux et al., 2015) and 2) catalase upregulation is associated with H 2 O 2 -specific damage rather than the oxidative damage induced by bleomycin which mainly involves the production of OH% − (Hay et al., 1991) . Moreover, quercetin also significantly decreases the pro-inflammatory cytokine production in vitro as well as ex vivo in a concentration-dependent manner in both IPF patients and controls. Interestingly, this quercetin effect is more pronounced in IPF patients. Taken together, our ex vivo results show that IPF patients have a reduced antioxidant capacity and increased inflammatory status while our in vitro data demonstrate that quercetin might be a potential therapy option as it reduces markers of inflammation and oxidative stress, thereby also boosting the antioxidant response. The fact that the anti-inflammatory effects of quercetin are more pronounced in the patients than in their matched controls indicates that especially patients suffering from diseases associated with oxidative stress are expected to profit from the use of antioxidant supplementation. To our knowledge, this is the first study that not only showed the protective effects of quercetin in vitro but also ex vivo in blood of IPF patients.
In agreement with our results, previous studies have reported the antioxidant properties of quercetin in in vitro models of IPF. It has been shown that quercetin is a potent activator of HO-1 expression as well as Nrf2 activity, indicated by nuclear translocation, in human fibroblasts after stimulation with the pro-fibrotic trigger TGF-β1 (Nakamura et al., Fig. 4 . Bleomycin dose-dependently induces IL-8 gene expression and production which can be reduced by quercetin pretreatment. (A) Gene expression of pro-inflammatory genes after stimulation with 10 μg/mL BLM with or without pretreatment with 25 μM quercetin. IL-8 production after stimulation with various concentrations of bleomycin after (B) 4 h and (C) 24 h of incubation. IL-8 production after pretreatment with different concentrations of quercetin and stimulation with bleomycin after (D) 4 h and (E) 24 h of incubation. Values are presented mean ± SEM (n = 6), *P < 0.05.
C. Veith et al. Toxicology and Applied Pharmacology 336 (2017) 40-48 2011). Similar effects of quercetin have also been reported in a murine alveolar epithelial cell line (Hayashi et al., 2012) . It is even suggested that quercetin is capable of inhibiting fibroblast activation, thereby ameliorating pro-fibrotic processes, indicated by collagen deposition in an experimental model of kidney fibrosis (Ren et al., 2016) . Besides lowering the occurrence of oxidative stress, reducing inflammation is also of great importance in IPF as pro-inflammatory cytokines can further evoke pro-oxidative and pro-fibrotic processes in the lung. Quercetin has recently been suggested to reduce markers of inflammation in vitro and in vivo. It has been shown that quercetin reduces pro-inflammatory cytokines in models of acute and chronic inflammation (Huang et al., 2015) via the regulation of nuclear factor kappalight-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein kinases (MAPK) pathways, thereby directly suppressing the induction of pro-inflammatory cytokines (Gardi et al., 2015; Tao et al., 2016) . Additionally, it has been shown before that ROS can induce the activation of several signaling pathways, including the redox-sensitive transcription factor NF-κB and MAPK, thereby inducing gene expression of various pro-inflammatory cytokines including TNFα, IL-8 and IL-1β (Schuliga, 2015; Mossman et al., 2006) . Consequently, it can be suggested that by reducing the amount of oxidative stress present in the cell, the release of pro-inflammatory cytokines can also be inhibited. This association between oxidative stress and inflammation can also be deducted from our results as the reduced antioxidant status of the IPF patients may explain the higher LPS-induced cytokine production in their blood and the more pronounced effects of quercetin hereon. Our results confirm this association as the antioxidant quercetin is not only lowering the oxidant burden but also reducing pro-inflammatory cytokine levels including IL-8 and TNFα. Interestingly, after LPS stimulation to evoke acute inflammation, quercetin concentration-dependently reduces these pro-inflammatory cytokines in both controls and IPF patients, although the effect is more pronounced in IPF patients in general and in their TNFα response in specific. It is known that TNFα is highly expressed in the lungs of IPF patients and contributes to the diseases pathogenesis by initiating pro-inflammatory and pro-fibrotic pathways (Rafii et al., 2013) . Although inhibition of TNFα reduces bleomycin-induced fibrosis in a mouse model (Piguet et al., 1989) , treatment with a TNFα antagonist (Etanercept) in IPF patients did not show significant improvements on lung function (Raghu et al., 2008) . It might therefore be more beneficial to reduce TNFα production in an indirect manner by using quercetin rather than blocking the effects of TNFα completely.
Some limitations can be observed in the current study setup. Cells were stimulated with bleomycin, which is a commonly used model to induce pro-fibrotic responses in vitro as well as in vivo whereas the patient samples were stimulated with LPS to mimic an additional inflammatory burden. These two different triggers were selected since there was no need to induce a pro-fibrotic response in in vivo samples obtained from patients suffering from pulmonary fibrosis. In vivo, the ongoing inflammation in the IPF patients included in our study was mapped by analyzing the anti-inflammatory cytokines IL-8 and TNF-α. IL-8, was selected due to its proven relation with IPF severity (Mukaida, 2003; Ziegenhagen et al., 1998) and the latter because anti-TNF-α agents have been suggested as treatment options for IPF. In vitro, the possible anti-inflammatory effects of quercetin during the onset of the disease were studied in an epithelial cell line that does not produce significant amounts of TNF-α but, since the involvement of IL-8 has already been proven in vivo as well, the focus of the present study was on this cytokine rather than on TNF-α.
To study the effect of quercetin, it is crucial that the study population has the same average intake of this dietary component. This average intake, which was approximately 15 mg per day, was estimated using food questionnaires. Since the patient samples were stimulated with quercetin ex vivo, an additional clinical supplementation study needs to be performed to confirm our results. Safety, dose and tolerability associated with the long-term usage of quercetin still needs to be investigated. The safety of quercetin is of particular interest as it has been shown that quercetin can induce inflammation when given in higher doses. Additionally, quercetin can be converted into oxidation products which might interact with sulfhydryl groups, thereby impairing critical cellular functions (de Franceschi et al., 2004) . Moreover, assessing the absolute effect of quercetin in the current patient cohort might be hampered by the fact that four of the included IPF patients were taking the GSH-precursor NAC, one the corticosteroid prednisone and five a combination at the time of inclusion.
In the last 25 years, a multitude of compounds have been tested in Cytokine production was related to that of the control incubation without quercetin (100%). Values are represented as mean ± SEM (controls n = 9, IPF n = 11), *P < 0.05, **P < 0.01.
C. Veith et al. Toxicology and Applied Pharmacology 336 (2017) [40] [41] [42] [43] [44] [45] [46] [47] [48] clinical trials of IPF, but with almost invariably negative results (Spagnolo et al., 2010) . Such high rate of failure was probably due to both incomplete knowledge of disease pathogenesis and the multitude and redundancy of mediators, growth factors and signaling pathways involved in the fibrotic process (Raghu et al., 2011a) . Interestingly, the most promising results within IPF treatment are currently acquired using strong antioxidants, underlining the important role of ROS within the pathology of this disease. A meta-analysis evaluating the efficacy of antioxidant therapy in IPF recently described that antioxidant therapy combined with other therapies is more beneficial in regard to lung function (e.g. carbon monoxide diffusing capacity) compared to monotherapy without added antioxidants (Kandhare et al., 2016) . However, anti-oxidant strategies with only NAC only have shown some potential benefits but cannot slow down the progression of the disease nor increase the overall survival (Woodcock and Maher, 2014) . Possible explanation for this limited effect could be that the antioxidant profile of NAC does not fit (Woodcock and Maher, 2014; Arts et al., 2004) . Instead, other therapeutic strategies with another type of antioxidant, more potently enhancing the compensatory Nrf2 antioxidant response, may prove to be more effective (Swamy et al., 2016) . Especially for IPF treatment, this induction of Nrf2 is important since this redox-sensitive transcription factor coordinately induces a variety of self-defense genes, including antioxidant and phase II detoxification enzymes (Singh et al., 2010b) . Based on our results, a perfect candidate for such specific and directed antioxidant therapy would be the dietary antioxidant quercetin. Future research will include comparison of different antioxidant strategies to quercetin as an additional supplement for IPF treatment.
In conclusion, our preliminary data indicate that a reduced antioxidant defense, causing a disturbed redox balance, and inflammation are two key triggers in the pathophysiology of IPF. Moreover, we have shown that adding quercetin to the current available treatment options might be beneficial in maximizing treatment effects and slowing down disease progression.
